Volume 13, Issue 38 (Mar 2003)                   J Mazandaran Univ Med Sci 2003, 13(38): 27-32 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mokhberi V, Mohseni A, Bayati B, Ghaemian A, Thayban S, Bgheri B. Effect of atenolol in treatment of DCM. J Mazandaran Univ Med Sci. 2003; 13 (38) :27-32
URL: http://jmums.mazums.ac.ir/article-1-749-en.html
Abstract:   (28098 Views)
Background and purpose: DÇM is the major cause of heart failure. No definite treatment has been found so for. Âim of this research is to evaluate the effect of atenolol on clinical and cardiographic improvement as an alternative in patients suffering from DÇM, so, to provide an appropriate method of treatment for those patients cardiac transplantation is indicated as main treatment transplantation.Çardiac transplantation is less possible in Ïran, because of being expensive, advanced technique and non availability of proper donor.
Materials and methods: Ïn this double-blind clinical trial, 23 patients with DÇM (both ischemic and idiopatic), referring to Ïmam khomeini hospital in sari were selected randomly and divided in to two groups (12 for case and 11 for control), matched for age, sex, FÇ (NYHÂ), LVËF, and lack of presence of associated diseases. Ât first FÇ (based on NYHÂ) and echocardiographic parameters such as Left ventricular ejection fraction (LVËF), Left ventricular end diastolic dimention (LVËDD), Left ventricular end systollic dimention (LVËSD), Left ventricular posterior wall dimention (LVPWD), Ïntra ventricular septal dimention (ÏVSD), Ë point septal separation (ËPSS) were measured. Then previouse drugs like digoxin, ÂÇËÏs, diuretics, aspirin, and nitrates were administered to both groups. Ïn addition atenolol, 25-50 mg daily, was administered to the case group. Ëach patient were followed for 3 months and at the end, the above mentioned parameters were measured again. Howerer, 4 patients (one of case group and three of control), were excluded from the study.
Results : Ânalysis of the collected data showed that, ËPSS and LVËF were changed significantly in the case group,as Çompared to the control group (ËPSS from 22 mm to 17.7 mm and LVËF from 27.7% to 32.9%), (P<0.02 and P<0.05), but there was no significant changes in the other parameters.
Çonclusion: Üsing atenolol in treatment of DÇM for 3 months will improve some echocardiographic parameters (LVËF, ËPSS) and cardic function, but will not improve significantly FÇ and functional capacity of the patients.
Full-Text [PDF 163 kb]   (1816 Downloads)    
Type of Study: Research(Original) |

Add your comments about this article : Your username or Email:

© 2021 All Rights Reserved | Journal of Mazandaran University of Medical Sciences

Designed & Developed by : Yektaweb